Anti–TNF-α inhibitor–induced lupus (often called anti‑TNFi lupus, ATIL, or TNF inhibitor–induced SLE) is a form of drug‑induced lupus that arises in the setting of TNF‑α blocker therapy, classically used for RA, psoriatic arthritis, ankylosing, spondylitis, inflammatory, bowel disease, and related conditions.
ATIL is a lupus‑like autoimmune syndrome temporally associated with exposure to TNF‑α inhibitors, with clinical and serologic features overlapping idiopathic SLE and resolving or improving after drug withdrawal.
All currently available TNF‑α inhibitors (e.g., infliximab, adalimumab, etanercept, certolizumab, golimumab) have been implicated, with infliximab and adalimumab reported most frequently in pharmacovigilance series.
Anti-TNF lupus is caused by a TNF inhibitor and affects 0.1 to 0.2% of patients taking such medications.
The overall risk is low compared with the number of exposed patients, but most cases are classified as serious events.
TNF‑α exerts complex immunoregulatory roles, including promoting clearance of apoptotic material and restraining autoreactive T cells; chronic blockade may impair these checks and favor autoantibody generation.
Hypothesized mechanisms include impaired clearance of nuclear debris, altered apoptosis via reduced CD44 expression, and reduced cytotoxic T‑cell–mediated deletion of autoreactive B cells, leading to ANA and anti‑dsDNA production.
Latency: months to several years after TNF‑α inhibitor initiation; can occur with any agent and after switching agents. – Clinical manifestations:
Constitutional: fever, malaise, weight loss.
Musculoskeletal: new or worsening polyarthritis or arthralgias, often symmetric.
Cutaneous: lupus‑like rash, photosensitivity, subacute cutaneous lesions; SLE rash and lupus‑like syndrome are frequent pharmacovigilance signals.
Serositis: pleuritis or pericarditis reported, including pericarditis‑predominant cases.
Serious organ involvement (lupus nephritis, CNS disease) appears less common than in idiopathic SLE.
ANA positivity or titer increase is very common during TNF‑α inhibitor therapy, even without clinical lupus; isolated ANA/anti‑dsDNA seroconversion does not by itself establish ATIL.
New anti‑dsDNA antibodies (IgG, IgM, IgA) are characteristic when clinical lupus develops and constitute strong supportive evidence for antilupus induced when correlated with symptoms.
Other autoantibodies (e.g., antihistone, antiphospholipid) may occur but are variable and less consistently reported.
Established exposure to TNF‑α inhibitor with appropriate latency.
Development of one or more clinical features compatible with SLE (rash, serositis, arthritis, cytopenias).
New or increased autoantibody formation (especially ANA and anti‑dsDNA) compared with baseline.
Reasonable exclusion of pre‑existing idiopathic SLE or other connective tissue tissues, a baseline immunologic workup recommended before TNF‑α inhibitor therapy where feasible.
Improvement or resolution of manifestations after drug discontinuation, usually over weeks to a few months.
Differential considerations:
Flare of the underlying inflammatory disease vs. true lupus‑like syndrome.
De novo idiopathic SLE incidentally occurring on therapy, rather than drug‑induced.
Other drug‑induced lupus etiologies (e.g., hydralazine, isoniazid, minocycline) and overlap CTDs.
Management
Discontinue the TNF‑α inhibitor once ATIL is strongly suspected, especially in the presence of systemic symptoms or organ involvement.
Monitor for clinical and serologic improvement; many patients experience resolution of lupus manifestations within weeks to months of withdrawal, though autoantibodies may persist longer.
Systemic therapy as needed based on severity:
Mild disease (arthralgia, rash, low‑grade serositis): low‑dose glucocorticoids, hydroxychloroquine, NSAIDs as appropriate.
Moderate to severe organ involvement: higher‑dose glucocorticoids, and conventional immunosuppressants (e.g., azathioprine, mycophenolate) tailored to phenotype, following SLE principles.
Re‑challenge with the same TNF‑α inhibitor is generally avoided; data on switching to another TNF‑α inhibitor are mixed, and many clinicians prefer a different biologic class (e.g., IL‑17/IL‑23, JAK inhibitor, abatacept, ustekinumab) depending on the underlying disease.
Baseline immunologic testing (ANA, ± anti‑dsDNA) before TNF‑α inhibitor initiation is advised to clarify pre‑existing autoimmunity and allow comparison if symptoms arise.
Routine serial ANA in asymptomatic patients is not universally recommended since ANA seroconversion alone is common and often clinically silent, but new symptoms should prompt repeat serology.
Brief comparison: ATIL vs classic drug induced lupus.
Common drug induced lupus agents: Infliximab, adalimumab, etanercept, and others Hydralazine, procainamide, isoniazid.
Autoantibodies | ANA and anti‑dsDNA frequent; other specificities variable.
ANA and antihistone classically prominent; anti‑dsDNA less consistent.
Organ involvement | Rash, arthritis, serositis; some nephritis/CNS but less than idiopathic SLE overall
Usually milder systemic; major renal/CNS involvement uncommon.
Drug-Induced Lupus: ATIL differs from classical drug-induced lupus by having more frequent cutaneous, renal, and cerebral involvement, as well as higher rates of dsDNA antibodies 
Typically improves/resolves over weeks–months; antibodies may persist. Similar pattern of improvement after drug cessation.
Incidence: The estimated incidence is approximately 0.19% for infliximab and 0.18% for etanercept  
In inflammatory bowel disease patients specifically, the pooled incidence is around 2.5%, with infliximab at 4.5% and adalimumab at 0.2% .
Most Common Causative Agents: Infliximab is the most common cause, followed by etanercept and adalimumab .
Clinical Presentation:
Symptoms range from mild cutaneous lesions to serious complications like pleural or pericardial effusions, deep venous thrombosis, pneumonitis, and neuritis .
Common symptoms include arthritis (87%), fatigue (42%), and mucocutaneous lesions (29%).
Two main forms exist: a limited form with skin manifestations and anti-DNA antibodies, and a more complete form with visceral involvement.
Most patients develop positive ANA (97%) and anti-dsDNA antibodies (74%).
Diagnosis requires a temporal relationship between symptoms and anti-TNF therapy, at least one serologic ACR criterion, and at least one non-serologic criterion like arthritis, serositis, or rash .
The primary treatment is discontinuation of the offending drug, with corticosteroids and immunosuppressive agents sometimes needed for full resolution.
Switching to a different anti-TNF agent is often well-tolerated without recurrence.
Baseline immunological testing should be done before starting anti-TNF therapy and monitor patients during treatment for lupus manifestations.